XENETIC BIOSCIENCES, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
XENETIC BIOSCIENCES, INC. (XBIO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$536.38K.
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.00M.
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.16M.
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$1.10M.
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $1.72M.
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$2.82M.
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$4.11M.
- XENETIC BIOSCIENCES, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$5.15M, a 176.63% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.41M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$536.38K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $1.72M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | -$2.04M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$1.39M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$1.00M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$2.82M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | -$2.14M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$1.68M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$1.16M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$4.11M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | -$3.32M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$2.37M 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$1.10M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$5.15M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | -$4.40M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$3.32M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$2.09M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $6.72M 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $8.18M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$2.25M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$1.52M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $1.16M 10-K · filed 2022-03-22 | |||
| 2020-09-30 | -$3.31M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$2.30M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$1.00M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $9.73M 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $11.41M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $396.10K 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $1.45M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$4.96M 10-K · filed 2020-03-26 | |||
| 2018-09-30 | -$3.92M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | -$2.27M 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | -$1.67M 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | $1.48M 10-K · filed 2019-03-29 | |||
| 2017-09-30 | -$3.35M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | -$1.72M 10-Q · filed 2018-08-10 | |||
| 2017-03-31 | $275.38K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |